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1. Introduction  
Nanoscience is the science of the phenomena peculiar to matter on the scale from 1 to 
several hundred nanometers (10-9 m). Some unique features of matter emerge when features 
are on the nanoscale, and the appreciation of these new properties opens new opportunities. 
Ignored in the past decades due to the lack of technology, these new emerging opportunities 
offered by nanoscience have been one of the most important areas of researching from the 
middle of the twentieth century to nowadays (Tibbals, 2010). 
New opportunities have been realized in a wide variety of areas of technology, ranging 
from intelligent nanoscale materials, faster electronics or nanomotors, to medicine and 
biology, where first nanotechnology applications have demonstrated an enormous potential. 
While medical nanotechnology was improving a wide range of medical resources and 
practice, the concept of nanomedicine was taking shape. Nanomedicine has recently been 
referred by the National Institutes of Health as the applications of nanotechnology for 
treatment, diagnosis, monitoring, and control of biological systems (Moghimi et al., 2005). 
Although this term has been defined in the literature in many ways, nanomedicine means 
essentially applying nanotechnology to medicine.  
In contrast with other therapies, nanomedicine attempts to use sophisticated approaches to 
either kill specific cells or repair them one cell at a time. This approach also offers new 
possibilities towards the development of personalized medicine (Gurwitz & Livshits, 2006). 
Because nanomedicine inherits its focus on certain diseases which are currently being 
investigated, its primary aims have been towards non-infectious diseases, especially cancer, 
and on degenerative diseases in order to characterize them in the increasingly sedentary and 
aging populations of the wealthiest countries that lead in medical research (Tibbals, 2010). 
One of the most important and hopeful tools employed in nanomedicine for medical 
applications are nanoparticles. Nanoparticles are solid, colloidal particles consisting of 
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macromolecular substances that vary in size from 10 nm to 1000 nm. However, particles 
>200 nm are not heavily pursued and nanomedicine often refers to devices <200 nm 
(i.e.,width of microcapillaries). Depending on the method of preparation nanoparticles, 
nanospheres, or nanocapsules can be constructed to possess different properties and release 
characteristics for the best delivery or encapsulation of the therapeutic agent (Barratt, 2000). 
One advantage of nanovectors—nanoparticles is their ability to overcome various biological 
barriers and to localize into the target tissue. The nanovectors currently used and 
investigated can be classified into three main groups or “generations” (Sakamoto et al., 
2007). The first generation comprises a passive delivery system that localizes into the target 
site. In case of a tumour, the system reaches the tumour through the fenestrations in the 
adjacent neovasculature, and is normally decorated by a "stealth" layer in order to avoid 
their uptake by phagocytic blood cells, thus substantially prolonging their circulation time 
(Romberg et al., 2008). The unique mechanism of driving systems to the tumour site is the 
size of particles, not specific recognition of the tumour or neovascular targets. As a case in 
point, particles based on albumin-paclitaxel have been recently aproved by FDA for their 
use in metastatic breast cancer (Kratz, 2008). The second generation of nanosystems includes 
additional functionalities that allow for molecular recognition of the target tissue or for 
active or triggered release of the payload at the disease site. These include ligands, aptamers 
and small peptides that bind to specific target-cell surface markers or surface markers 
expressed in the disease microenvironment (Kang et al., 2008). Responsive systems, such as 
pH-sensitive polymers, are included in this cathegory. Although the representatives of the 
second generation have not yet been approved by the FDA, there are numerous ongoing 
clinical trials involving targeted nanovectors, particularly in cancer applications. Finally, the 
third generation nanovectors are focused to successfully overcome the natural barriers that 
the vector needs to bypass to efficiently deliver the drug to the target site. This goal will only 
be reached by a “multistage” approach, and such a system has been recently reported 
(Tasciotti et al., 2008). 
Polymeric nanoparticles made from natural and synthetic polymers have received the 
majority of attention due to their stability and ease of surface modification. Polymeric 
materials used for preparing nanoparticles for drug delivery must be biocompatible at least 
and biodegradable best. Among natural polymers, proteins or polysaccharides tend to be 
internalized and degraded rapidly, thus enabling a moderate intracellular release of the 
drug or gene (Sinha & Trehan, 2003). Polysaccharides have been especially used in the 
preparation of drug delivery systems. 
Polysaccharides are the polymers of monosaccharides. In nature, polysaccharides have 
various resources from algal origin (e.g.alginate), plant origin (e.g. pectin, guar gum), 
microbial origin (e.g. dextran, xanthan gum), and animal origin (chitosan, chondroitin) 
(Sinha & Kumria, 2001). They offer a wide diversity in structure and properties due to their 
wide range of molecular weight and chemical composition. 
Due to the presence of various reactive groups in their structure, polysaccharides can be 
easily modified chemically and biochemically. Moreover, the presence of hydrophilic 
groups in their structure, such as hydroxyl, carboxyl and amino groups, enhance 
bioadhesion with biological tissues, like epithelia and mucous membranes, forming non-
covalent bonds, which is an useful strategy to improve bioavailability of drugs included in 
drug delivery systems (Lee et al., 2000). 
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One of the main advantages of polysaccharides as natural biomaterials is their availability in 
natural resources and low cost in their processing, which make them very accessible 
materials to be used as drug carriers. Furthermore, polysaccharides are highly stable, safe, 
non-toxic, hydrophilic and biodegradable (Liu et al., 2008).Thus, they have a large variety of 
composition and properties that cannot be easily mimicked in a chemical laboratory, and the 
ease of their production makes numerous polysaccharides cheaper than synthetic polymers 
(Coviello et al., 2007). Therefore, polysaccharides have a promising future as biomaterials. 
In recent years, a large number of studies have been conducted on polysaccharides and their 
derivatives for their potential application as nanoparticle drug delivery systems. The 
number of polysaccharides that have been investigated for the preparation of nanoparticles 
suitable as delivery systems is extremely large. As a result, attention has been focused on the 
latest studies and exploitations related to such systems, including some of the most used 
polysaccharides, a brief description of their structural features and some of the techniques 
carried out to prepare polysaccharide-based nanoparticles. 
2. Structural features and characteristics of polysaccharides 
As the number of polysaccharides used in the preparation of drug delivery systems is very 
large, some of the most commonly used polymers have been collected, describing their 
chemical structure, chemical features, and highlighting their applications in different fields, 
especially, in the preparation of drug delivery systems. 
2.1 Alginate 
Alginate is a well known polysaccharide obtained from natural sources, such as its 
extraction from cell walls and intercellular spaces of marine brown algae, and its production 
by bacteria. It can be characterized as an anionic copolymer whose chemical structure is 
based on a backbone of (1-4) linked ǃ- D-mannuronic acid (M units) and ǂ-L-guluronic acid 
(G units) (Fig. 1) of widely varying composition and sequence depending on the source of 
the alginate, resulting in an irregular blockwise pattern of GG, MG and MM blocks. Alginate 
has a variable molecular weight, depending on the enzymatic control during its production 
and the degree of depolymerization caused by its extraction. Typically, commercial alginates 
have an average molecular weight of approximately 200,000 Da, but alginates with values as 
high as 400,000-500,000 Da are also available (Rehm, 2009). 
  
Fig. 1. Chemical structure of alginate 
The physico-chemical properties of alginate have been found to be highly affected by the 
M/G ratio as well as by the structure of the alternating zones, which can be controlled by 
enzymatic pathways (Coviello et al., 2007). The alginate composition influence on the 
flexibility of the polysaccharide chain was first reported by Smidsrod (1973), who described 
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that the extension of the alginate chain was dependent on its composition, with the intrinsic 
flexibility of the blocks decreasing in the order MG>MM>GG. M block segments show 
linear and flexible conformation because of the ǃ (1→4) linkages. Besides, the guluronic acid 
gives rise to ǂ (1→4) linkages, which serves to introduce a steric hindrance around the 
carboxylic groups, and provide folded and rigid structural conformations that are 
responsible for a pronounced stiffness of the molecular chains (Yang et al., 2011).  
Alginate is a biopolymer and a polyelectrolyte considered to be biocompatible, non-
inmunogenic, non-toxic and biodegradable, and the composition of the polymer has been 
reported to affect to its applications. Alginate with high content of guluronic acid block can 
produce, in the form of calcium salts, cross-links stabilizing the structure of the polymer in a 
rigid gel form. This properly enables alginate solutions to be processed into the form of 
films, beads and sponges (Sujata, 2002). However, high mannuronic acid alginate capsules 
are interesting for cell transplantation and for biohybrid organs, because of their less 
viscosity. In the case of cellular response, some research groups found immunostimulatory 
activity caused by those alginates with high mannuronic acid content, and 
immunosuppressive activity caused by alginates with high guluronic acid content. It was 
concluded that mannuronic acid oligomers would provoke cytokine release by macrophages 
by a receptor-mediated mechanism, whereas guluronic oligomers should inhibit this 
reaction (Orive et al., 2002). 
Compositional modifications of natural alginates can be obtained by several mannuronan  
C-5 epimerases produced by alginate-producing bacteria, such as A. vinelandii. Recently, the 
combination of different epimerases has been used as a fundamental tool in order to create 
specific engineered alginates with any desired block length and composition (Rehm, 2009). 
Moreover, alginate has a large number of free hydroxyl and carboxyl groups distributed 
along the backbone, which are highly reactive and turn it into an ideal candidate for being 
appropriately modified by chemical functionalization. Thus, properties such as solubility, 
hydrophobicity and physicochemical and biological characteristics may be modified, having 
proved alginate derivatives to have a lot of potential applications. These chemical 
modifications of alginate have been achieved using techniques such as oxidation, sulfation, 
esterification, amidation, or grafting methods (Yang et al., 2011).  
Due to its abundance, low price and non-toxicity, alginate has been extensively used in 
different industries. For instance, it has been used as food additive and thickener in salad 
dressings and ice-creams in the alimentary industry (Nair & Laurencin, 2007). Moreover, the 
biocompatibility behavior and the high functionality make alginate a favorable biopolymer 
material for its use in biomedical applications, such as scaffolds in tissue engineering 
(Barbosa et al., 2005), immobilization of cells (Lan & Starly, 2011), and controlled drug 
release devices (Pandey & Ahmad, 2011).  
In case of its applications in nanomedicine, alginate has also been extensively investigated 
as a drug delivery device in which the rate of drug release can be modified by varying the 
drug polymer interaction, as well as by chemical immobilization of the drug in the polymer 
backbone using the reactive carboxylate groups (Nair & Laurencin, 2007). Apart from its 
easy functionalization due to its reactive structure, there are many advantages and favorable 
properties of alginate for its use in drug delivery. It is a natural polymer compatible with a 
wide variety of substances, which does not need multiple and complex drug-encapsulation 
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process. Moreover, it is mucoadhesive and biodegradable and, consequently, it can be used 
in the preparation of controlled drug-delivery systems achieving an enhanced drug 
bioavailability (Pandey & Ahmad, 2011).  
Therefore, the biocompatibility, availability and versatility of this polysaccharide make it an 
important and hopeful tool in the field of nanomedicine, especially in the preparation of 
nanoparticulate drug delivery systems. 
2.2 Chitosan 
Chitosan is a linear polysaccharide composed by units of glucosamine and N -acetyl-
glucosamine linked by (1 → 4) ǃ-glycosidic bonds (Fig. 2). It is a hydrophilic biopolymer 
obtained industrially by hydrolysing the aminoacetyl groups of chitin — which is the main 
component of the shells of crab, shrimp and krill — by an alkaline deacetylation treatment 
(Muzzarelli & Muzzarelli, 2005). 
The degree of deacetylation (%DD) can be determined by NMR spectroscopy, and generally 
the %DD in commercial chitosan is in the range 60–100%. On average, the molecular weight 
of commercially produced chitosan is between 3,800 to 20,000 Da. A commonly used 
method for the synthesis of chitosan is the deacetylation of chitin, using sodium hydroxide 
in excess as a reagent and water as a solvent. This reaction pathway, when allowed to go to 
completion (complete deacetylation), yields up to 98% product (Yuan, 2007). So, once 
deacetylation happens, chitosan is consisting primarily of repeating units of ǃ-(1,4)-2-amino-
deoxy-D-glucose (D-glucosamine). 
 
Fig. 2. Chemical structure of chitosan. 
This biopolymer is accepted as a biodegradable and non toxic polymer. Despite its 
biocompatibility, the applications of chitosan are limited due to its insolubility above pH 6. 
Chitosan is a weak base and it is insoluble in water and organic solvents. However, it is 
soluble in diluted aqueous acidic solution (pH <6.5), which can convert the glucosamine 
units into a soluble form with protonated amine groups (Sinha et al., 2004). It is possible to 
increase the solubility of chitosan in water removing one or two hydrogen atoms from the 
amino groups of chitosan, and introducing some hydrophilic segments (Srinophakun & 
Boonmee, 2011). 
The non-toxic, biodegradable and biocompatible properties of chitosan provide potential for 
many applications (Guerrero et al., 2010). Due to its polyelectrolyte nature, chitosan can be 
used as absorbent for treatment of textile industry effluents as well as for heavy metal ions 
uptaking from wastewater. It has been also used as template for the preparation of 
mesoporous metal oxides spheres (Braga et al., 2009). However, it has been more frequently 
proposed for applications in pharmaceutical and biomedical fields due to its 
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biocompatibility and biodegradability. It has been assayed as biomaterial for wound healing 
and prosthetic material, since it can be biodegraded by enzyme action (Bernardo et al., 
2003). Also it is reported to find applications as an antimicrobial compound, as a drug in the 
treatment of hyperbilirubinaemia and hypercholesterolaemia and, also, it has been prepared 
and evaluated for its antitumour activity carrying several antineoplastic agents (Blanco et 
al., 2000).  
In the field of nanomedicine, chitosan has attracted attention as a matrix for controlled 
release due to its reactive functionalities, polycationic character, easily degradation by 
enzymes and non-toxic degradation products. Over the years, a variety of natural and 
synthetic polymers have been explored for the preparation of drug-loaded microparticles 
and chitosan has been extensively investigated (Davidenko et al., 2009; Muzzarelli & 
Muzzarelli, 2005). Because of its bioadhesive properties, chitosan has received substantial 
attention as carrier in novel bioadhesive drug delivery systems which prolong the residence 
time of the drugs at the site of absorption and increase the drug bioavailability (Varum et al., 
2008). Thus, some drugs administered via nasal (Learoyd et al., 2008) or gastrointestinal 
routes have improved their treatment efficacy when they are included into chitosan-based 
systems (Guerrero et al., 2010). 
Taking all into account, chitosan appears to be a promising matrix for the controlled release 
of pharmaceutical agents. Experimental in vitro and in vivo results show chitosan as an ideal 
carrier for a wide variety of drugs whose efficacy is increased when they are included into 
these systems.  
2.3 Hyaluronic acid 
Hyaluronic acid (HA) (also called sodium hyaluronic or hyaluronan) is a polysaccharide 
with a structure composed of repeating disaccharide units of D-glucuronic acid and N-
acetyl D-glucosamine linked by ǃ (1-3) and ǃ (1-4) glycosidic bonds (Fig. 3) (Cafaggi et al., 
2011). HA can be modified in many ways to alter the properties of the resulting materials, 
including modifications leading to hydrophobicity and biological activity. There are three 
functional groups that can be chemically modified: the glucuronic acid carboxylic acid, the 
primary and secondary hydroxyl groups, and the N-acetyl group (Burdick & Prestwich, 
2011). HA has a molecular weight that can reach as high as 107 Da.  
 
Fig. 3. Chemical structure of disaccharide repeating unit of hyaluronic acid. 
It belongs to a group of substances known as glycosaminoglycans. It is the most simple 
among them, the only one not covalently associated with a core protein, and the only one 
which is non-sulfated (Kogan et al., 2007). Since hyaluronan is a physiological substance, it 
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is widely distributed in the extracellular matrix of vertebrate tissues. It is mainly 
synthesized in vertebrate organisms as an essential functional component due to its 
viscoelastic and rheological properties. It is a major and important component of cartilage, 
skin and synovial fluid.  
HA is usually linked to other biopolymers in the organism, and several separation 
procedures have to be applied in order to obtain the pure compound, such as protease 
digestion, HA ion-pair precipitation, membrane ultrafiltration, HA non-solvent 
precipitation and/or lyophilisation (Mendichi & Soltes, 2002). With these methods HA from 
several hundred thousand Da up to 2.5 MDa can be obtained. However some 
microorganisms secreted HA with a molar mass in the range of several MDa, such as 
attenuated strains of Streptococcus zooepidemicus and S. Equi. Bacillus subtilis has been recently 
genetically modified to culture a proprietary formula to yield hyaluronans (Mendichi & 
Soltes, 2002). 
It is a biodegradable, bioactive, non inmunogenic, non cytotoxic and negatively charged 
polysaccharide (Oh et al., 2010) that has been associated with several cellular processes, 
including angiogenesis and the regulation of inflammation (Leach & Schmidt, 2005).  
Among its applications, it is widely used as a coating for the surface modification of various 
biomaterials used for prosthetic cartilage, vascular graft, guided nerve regeneration and 
drug delivery (Li et al., 2006). 
Like other glycosaminoglycans, hyaluronan can serve as a targeting vehicle for the delivery 
of chemotherapeutic agents to cancerous tissues, as many tumours over express the 
hyaluronan CD44 and RHAMM receptors (Yip et al., 2006). As a drug delivery carrier, HA 
has several advantages including the negligible non-especific interaction with serum 
components due to its polyanionic characteristics (Ito et al., 2006) and the highly efficient 
targeted specific delivery to the liver tissues with HA receptors (Zhou et al., 2003).  
More recently, HA has become recognized as an important building block for the creation of 
new biomaterials with utility in tissue engineering and regenerative medicine (Allison & 
Grande-Allen, 2006; Prestwich, 2008). Moreover, it has been shown that HA binds to cells 
and effectively promotes new bone formation. Balazs classified the biomedical applications 
of the HA and its derivatives in areas as vicosurgery, viscoaugmentation, viscoseparation, 
viscosupplementation, viscoprotection (Balazs, 2004).  
So, in this way, there is a wide number of usages of HA in medicine and cosmetics, such as 
ophthalmology, orthopaedic surgery and rheumatology, otolaryngology, wound healing, 
pharmacology and drug delivery (Kogan et al., 2007), which shows HA as a successful 
biomaterial used in different fields of biomedicine. 
2.4 Dextran 
Dextran is a polysaccharide made of many glucose molecules composed of chains of varying 
lengths. It has a substantial number of  (1→6) glucosidic linkages in its main chain (Fig. 4), 
and a variable amount of  (1→2),  (1→3) and  (1→4) branched linkages (Misaki et al., 1980). 
The degree and type of branching will be determined by the bacterial strain that synthesizes it. 
Its average molecular weight is as high as 107 - 108 Da (Heinze et al., 2006) but can be reduce by 
acidic hydrolysis obtaining molecular weight fractions that also can interest.  
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Fig. 4. Chemical structure of dextran with  (1→3) branched linkage. 
The natural structure of dextran can be modified by reacting different molecules (such 
hydrophobic molecules) with its different hydroxyl groups (Lemarchand et al., 2003b). 
Many amphiphilic dextran derivates have been obtained by varying the nature of the 
reacting molecules (aromatic rings, aliphatic or cyclic hydrocarbons) and the number of 
grafted, that is the number of hydrophobic groups per 100 glucopyranose units or the 
degree of substitution (Rotureau et al., 2004). 
Dextran is neutral, water soluble, biocompatible and biodegradable. Its features may vary 
depending on the molecular mass as well as the distribution, type of branches and the 
degree of branching, which depend on the bacterial synthesis or post-synthesis reactions to 
form derivatives. 
Dextran is synthetized by a wide variety of bacterial strains. Leuconostoc mesenteroides 
produces dextran from sucrose and Gluconobacter oxydans produces dextran from 
maltodextrin. Streptococcus mutans also produces dextran from sucrose (Heinze et al., 2006). 
It can be also obtained enzimatically using cell-free culture supernatant (Wang et al., 2011). 
Apart from these methods, dextran can be also produced by chemical synthesis, developing 
a cationic ring opening polymerisation of levoglucosan (Heinze et al., 2006). 
It has wide applications in different areas such as pharmaceutical, chemical, clinical, and food 
industry. Dextran is used as a drug (as blood plasma volume expander), adjuvant, emulsifier, 
carrier, stabilizer and thickener of jam and ice cream. Also it is widely used for the separation 
and purification of proteins (Naessens et al., 2005) based on size exclusion chromatography 
with a matrix of cross-linked dextran gel layer. Its derivatives also have multiple applications 
depending on the characteristics that structural modifications give them.  
Both dextran and its derivatives have potential application for the preparation of modified 
drug delivery (Aumelas et al., 2007; Coviello et al., 2007; Chen et al., 2003). Not only has this 
polysaccharide been used to prepare nanoparticulate systems as a carrier, but also it has 
been employed to cover these systems (Gavory et al., 2011). 
It seems that dextran is a very useful tool in the field of nanomedicine, showing also good 
availavility, biocompatibility and biodegradability, being selected by a lot of researchers as 
biomaterial in the preparation of nanosystems. 
2.5 Other polysaccharides 
2.5.1 Pullulan 
Pullulan is a linear bacterial homopolysaccharide produced from starch by the fungus 
Aureobasidium pullulans. The backbone is formed by glycosidic linkages between ǂ-(1→6) D-
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glucopyranose and ǂ-(1→4) D-glucopyranose units in a 1:2 ratio (Fig. 5). The molecular 
weight of pullulan range from thousands to 2,000,000 Da depending on the growth 
conditions (Rekha & Chandra, 2007).  
 
Fig. 5. Chemical structure of pullulan. 
The backbone structure of pullulan tends to behave as a random expanded flexible coil in 
aqueous solution with modelling studies suggesting that this flexibility is imparted by the ǂ-
(1→6) linkage. This could be the reason why pullulan is biodegradable and has high 
adhesion, structural flexibility and solubility (Leathers, 2003). Pullulan can also be easily 
derivatized in order to impart new physico-chemical properties, e.g. to increase the 
solubility in organic solvents or to introduce reactive groups. 
This polysaccharide has numerous uses: in foods and beverages as a filler; as an edible, 
mostly tasteless polymer, the chief commercial use of pullulan is in the manufacture of 
edible films that are used in various breath freshener or oral hygiene products; in 
pharmaceuticals as a coating agent; in manufacturing and electronics it is used because of its 
film- and fiber-forming properties. It is worth noting that pullulan films, formed by drying 
pullulan solutions, are clear and highly oxygen-impermeable and have excellent mechanical 
properties.  
Due to it is hemocompatible, non-immunogenic, non-carcinogenic, FDA approved it for a 
variety of applications (Coviello et al., 2007). Recently, pullulan has been investigated for 
being used in various biomedical applications such as drug and gene delivery (Rekha & 
Chandra, 2007), tissue engineering (Thebaud et al., 2007), and wound healing (Bae et al., 
2011).  
Numerous papers deal with pullulan hydrogels as drug delivery systems, particularly in the 
form of micro and nanogels. Despite pullulan is not a natural gelling polysaccharide, an 
appropriate chemical derivatization of its backbone can actually lead to a polymeric system 
capable of forming hydrogels. The study of nanogels has been intensified over the last 
decade due to related potential applications in the development and implementation of new 
environmentally responsive or smart materials, biomimetics, biosensors, artificial muscles, 
drug delivery systems and chemical separations (Coviello et al., 2007).  
In order to obtain nanostructures that may act as carriers of different drugs, the backbone 
structure of pullulan is modified with hydrophobic molecules, resulting in a molecule of 
hydrophobized pullulan that self-assembles in water solutions. Cholesterol, hexadecanol or 
vitamin H are some molecules that are attached to the structure of pullulan in order to 
obtain micelles in water solution (Liu et al., 2008). 
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2.5.2 Guar gum 
Guar gum is a water soluble polysaccharide extracted from the seeds of Cyamopsis 
tetragonoloba, which belongs to Leguminosae family. Also called guaran, it is a non-ionic 
natural polysaccharide derived from the ground endosperm of guar beans. Its backbone 
consists of linear chains of (1 → 4)-ǃ-D-mannopyranosyl units with ǂ-D-galactopyranosyl 
units attached by (1 → 6) linkages (Fig. 6), forming short side-branches (Sarmah et al., 2011).  
OOH
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OHOH
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O OH
CH2OH
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n  
Fig. 6. Chemical structure of guar gum.  
Guar gum hydrates in cold water to form a highly viscous solution in which the single 
polysaccharide chains interact with each other in a complex way (Barbucci et al., 2008). Its 
nine hydroxyl groups are available for the formation of hydrogen bonds with other 
molecules, but it remains neutrally charged due to the absence of dissociable functional 
groups. Extreme pH and high temperature conditions (e.g. pH 3 at 50°C) degrade its 
structure (Tiraferri et al., 2008). It remains stable in solution over pH range 5-7. Strong acids 
cause hydrolysis and loss of viscosity, and alkalis in strong concentration also tend to reduce 
viscosity. It is insoluble in most hydrocarbon solvents.  
As the guar gum polymer is a low-cost, easily available and non-toxic polysaccharide, it is 
widely applied in many industrial fields. Thanks to its property of producing highly viscous 
aqueous solutions, it is commonly used as a thickening agent in cosmetics and in sauces, 
salad dressings and ice creams in the food industry (Barbucci et al., 2008). In 
pharmaceuticals, guar gum is used in solid dosage forms as a binder and disintegrant, and it 
has also been used as hydrophilic matrix, for designing oral controlled release dosage forms 
(Sarmah et al., 2011). Guar gum has been extensively used for colon delivery due to its drug 
release retarding property and susceptibility to microbial degradation in the large intestine 
(Soumya et al., 2010). 
Not only the native guar-gum is used, but also chemically modified products can be used 
with the objective of changing its intrinsic characteristics of solubility, viscosity and 
rheological behaviour. For instance, hydrossilalchyl derivatives, which are often used for the 
formulation of cements and plasters, or carboxymethyl derivatives, which are employed as 
thickening agents.  
In case of biomedical fields or pharmaceutical fields, such as 3D scaffolds for cell culture, 
fillers for tissue engineering and carriers for drugs, the physically cross-linked product is 
obtained through a spacer arm between the polymer chains and allows the obtainment of an 
insoluble compound in a wide range of pH with a good mechanical stability (Barbucci et al., 
2008).  
Little information is available in the literature for the possibility of using guar gum based 
nanosized materials as drug carriers due to its solubility in water, what makes difficult to 
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use it as adsorbent in aqueous conditions. Some researchers have incorporated to its 
structure some compounds like silica, in order to obtain insoluble compounds which could 
act as adsorbents in aqueous media (Singh et al., 2009). Moreover, guar gum-based 
nanosystems have been prepared by nanoprecipitation and cross-linking methods (Soumya 
et al., 2010). A different application of this polysaccharide has been found as stabilizer of 
nanosuspensions, where the presence of guar gum during the synthesis process allows the 
achievement of a better stability of the nanoparticles (Tiraferri et al., 2008). 
2.5.3 Pectin 
Pectin is a structural polysaccharide obtained from the cell wall of all plants, where is 
implicated in cell adhesion. This natural polymer has a heterogeneous chemical structure 
based on large amounts of poly (D-galacturonic acid) bonded via ǂ (1 → 4) glycosidic 
linkage (Fig. 7). Pectin has a few hundred to about one thousand building blocks per 
molecule, corresponding to an average molecular weight of about 50,000 to about 180,000 
Da (Sinha & Kumria, 2001). The carboxyl groups are partially in the methyl ester form with 
different degree of esterification (DE) and amidation (DA), which determine the content of 
carboxylic acid in pectin chains. 
  
Fig. 7. Chemical structure of pectin 
In the beginning, applications of pectin concentrated in food industry, as gelling or 
thickening agent, but lately it started being also used as an excipient for pharmaceutical 
purposes (Liu et al., 2003). Nowadays, some of the uses of pectin in biomedical applications 
include the facilitation of the delivery of specific sequences of amino acids, anti-
inflammatory agents, anti-coagulants, and wound healing substances to tissue sites. Also, 
pectin remains intact in the physiological environment of the stomach and the small 
intestine, but is degraded by pectinases, which are secreted by the bacteria inhabitants of the 
human colon. Due to these properties it is highly possible that pectin could function as a 
delivery vehicle to escort protein and polypeptide drugs from the mouth to the colon (Sinha 
& Kumria, 2001). To be used as such, pectin based composites can be formed into 
membranes, microspheres, scaffolds, or injectable gels (Liu et al., 2004). 
The most attractive property of pectin for industrial applications is its gelling activity. 
Parameters such as type and concentration of pectin (DE, DA), modification of hydroxyl 
groups, pH, temperature and the presence of cations, determine the gel process. For example, 
a high DE of pectin provides the gel formation, increasing the amounts of hydrophobic areas 
and reducing the solubility of pectin. In contrast, when the DE is less than 50%, pectin is highly 
water soluble and gel formation is only at extremely low pH solution or in the presence of 
divalent cations, which cross-link the galacturonic acids of the main polymer chains (Liu et al., 
2003). Also, it is possible to reduce the hydrophilic property with an increasing tendency to 
form gels by the introduction of amide groups in low DE pectin.  
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With regard to its use in the preparation of drug delivery systems, pectin is not able to 
shield its drug load effectively during its passage through the stomach and small intestine 
due to its high water-solubility (Sinha & Kumria, 2001). Consequently, most of the 
researching groups focused on looking for water resistant pectin derivatives, which were 
also enzymatically degradable. For this purpose, calcium salts binding by non-covalent 
associations with the carbohydrate chains of pectin were investigated, which can reduce the 
solubility and are stable in low pH solution while resisting extensive hydration in vivo in the 
gastrointestinal tract. Thus, calcium pectinate is a potential candidate as a drug carrier for 
colon-specific delivery in different formulations such as microspheres, films, gels or droplets 
(Liu et al., 2003). Another derivative of pectin, amidated pectin cross-linked with calcium, 
was considered for colonic delivery, with retarding drug release and because of its 
biodegradability, higher tolerance to pH variations and fluctuations in calcium levels (Sinha 
& Kumria, 2001). 
In addition, combinations of pectin with other polymers, either naturally occurring or 
synthetic, have been developed in order to obtain useful novel formulations. The 
combination of pectin and a second polymer into a composite may alter degree of swelling 
and change mechanical properties (Liu et al., 2003), improving in the most cases the stability 
of the drug and controlling the drug release. As a case in point, pectin has been combined 
with 4-aminothiophenol (Perera et al., 2010), chitosan (Fernandez-Hervas & Fell, 1998), 
hyaluronic acid (Pliszczak et al., 2011) or poly (lactide-co-glycolide) (Liu et al., 2004), 
showing good results as controlled drug release devices. 
3. Preparation methods of polysaccharide-based nanoparticles 
As for polysaccharide-based nanoparticles, it can be seen in the literature wide research 
carried out focusing on the preparation and application of these systems, which enhances 
their importance and versatility in terms of category and function.  
According to the literature and the structural features of the employed polysaccharides, five 
mechanisms can be mainly applied in order to obtain nanoparticles, namely gelation of 
emulsion droplets, covalent cross-linking, ionic cross-linking, self-assembling and 
nanoprecipitation. 
3.1 Formation of nanoparticles from an emulsion: nanoparticles obtained by gelation 
of emulsion droplets  
Different methods to prepare emulsified systems have been significantly developed. All of 
them require two immiscible phases and the presence of a surface active agent, whose 
nature has been already evolved, replacing the commonly used pluronic or span by new 
amphiphilic copolymers (Qiu & Bae, 2006). These methods are two-step processes, where 
the first step consists of the preparation of an emulsified system while nanoparticles are 
formed during the second step. Generally, the principle of the second step gives its name to 
the method (Vauthier & Bouchemal, 2009). 
Nanoparticles can be obtained from an emulsion method by gelation of the emulsion 
droplets where the polymer is dissolved, and that have been formed in the first step of the 
emulsion procedure. Polysaccharides show good gelling properties as well as good 
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solubility in water, which make them ideal candidates to be used for preparing 
nanoparticles by this method (Vauthier & Couvreur, 2000). Different mechanisms of gelation 
can be applied depending on the gelling properties of the polymer. Changes in temperature 
of the emulsion system or gelation induced by covalent or ionic cross-linking are some of 
these mechanisms which induce the gelation of the pre-formed droplets and allow 
nanoparticles to be obtained.  
Alginate and pectin particles have been obtained by using a modified 
emulsification/internal gelation method (Opanasopit et al., 2008). The preparation of two 
different emulsions is required: one containing the gelling polymer in the dispersed phase 
and the other containing the gelling agent (usually counter-ions) or the pH controlling agent 
in the dispersed phase. Both emulsions are mixed together under strong stirring conditions 
in order to achieve collisions between droplets, which are necessary to promote the gelation 
of the polymer and, consequently, the formation of nanoparticles (Fig. 8). In case of alginate, 
the size range of particles is greatly dependent on the order of addition of counter-ion to the 
alginate solution. Some studies show that the addition of a polyelectrolyte complexation 
step in this procedure shows some benefits in order to obtain a better control of size 
distribution. Dextran or chitosan can be used as complexing agents in the in situ gelation of 
the droplets obtained in the previous nanoemulsion (Reis et al., 2007). The resulting 
nanoparticles range in size from 267 nm to 2.76 µm.  
 
Fig. 8. Schematic representation of the emulsification-internal gelation technique using 
alginate. 
Chitosan particles have been formed from an emulsified system by emulsion cross-linking 
method or by emulsion-droplet coalescence method. In the first method, the reactive 
functional amine group of chitosan reacts with aldehyde groups of the cross-linking agent, 
which usually is glutaraldehyde. A water-in-oil (w/o) emulsion is prepared by emulsifying 
the chitosan aqueous solution in the oil phase. Aqueous droplets are stabilized using a 
suitable surfactant. The stable emulsion is cross-linked by glutaraldehyde to harden the 
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droplets. Microspheres are filtered and washed repeatedly with n-hexane, followed by 
alcohol and then dried (Akbuga & Durmaz, 1994). Particle size can be determined by 
controlling the size of aqueous droplets, but it is usually ranged in a micrometric scale 
(Kumbar & Aminabhavi, 2003).  
Chitosan nanoparticles with a mean size of 400 nm can be obtained by emulsion-droplet 
coalescence method. This method, introduced by Tokumitsu and coworkers (Tokumitsu et 
al., 1999), utilizes the principles of both emulsion cross-linking and precipitation. A stable 
emulsion containing aqueous solution of chitosan and the encapsulant drug is produced in 
liquid paraffin. Another emulsion containing NaOH aqueous solution is produced in the 
same manner and is finally mixed with the other under high speed stirring. Droplets of each 
emulsion would collide at random and coalesce, precipitating chitosan droplets to give 
small solid particles.  
With a polymer like agarose, gel beads can be formed by cooling down the temperature of 
the solution which is prepared at high temperature. Thermal gelation results from the 
formation of helicoidal structures responsible for a three-dimensional network in which 
large amounts of water can be entrapped. The hydrogel, being hydrophilic, inert, and 
biocompatible, forms a suitable matrix for macromolecules that can be entrapped in the gel 
during formation (Vauthier & Couvreur, 2000). Agarose nanoparticles are produced using 
an emulsion-based technology which requires the preparation of an agarose solution in corn 
oil emulsion at 408ºC. Macromolecules to be encapsulated are initially added to the agarose 
solution. The small size of the dispersed aqueous nanodroplets is achieved by 
homogenization. Gelation of agarose is then induced by diluting the emulsion with cold 
corn oil under agitation at 58ºC. The liquid nanodroplets then gel to macromolecule-
containing agarose hydrogel nanoparticles (Wang & Wu, 1997). The mean average size of 
the obtained nanoparticles is 504 nm. 
3.2 Polysaccharide-based nanoparticles with covalent cross-links  
Among various polysaccharides, chitosan is the early one to be used to prepare 
nanoparticles based in covalent cross-links. Glutaraldehyde has been usually used as a 
cross-linker to obtain nanoparticles by emulsion cross-linking method (previously 
described), but its citotoxicity limits its utility in the field of drug delivery systems. 
However, some chitosan nanoparticles are still being produced using glutaraldehyde as 
cross-linker agent (Zhi et al., 2005).  
To overcome the problems of toxicity that are presented by glutaraldehyde, some 
biocompatible cross-linkers, such as natural di- and tricarboxylic acids, including succinic 
acid, malic acid, tartaric acid and citric acid, are used for intermolecular cross-linking of 
chitosan nanoparticles (Bodnar et al., 2005). By this method, the pendant amino groups of 
chitosan react in aqueous media with carboxylic groups of natural acids which were 
previously activated by a water-soluble carbodiimide, obtaining polycations, polyanions, 
and polyampholyte nanoparticles with an average size in the range of 270–370 nm 
depending on the pH. 
Hyaluronic acid is another polysaccharide used to prepare nanoparticles by using a 
carbodiimide method. The preparation of nano-sized particulate systems based on 
hyaluronic acid takes place by covalently cross-linking via carboxyl groups of the 
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hyaluronic acid chain with a diamine in aqueous media at room temperature. Bodnar and 
coworkers have obtained spherical nanoparticles whose size varies less than 130 nm 
(Bodnár et al., 2009).  
Recently, nanoparticles based on thiolated alginate and modified albumin have been 
synthesized and stabilized by the formation of disulphide bonds between both polymers 
(Martínez et al., 2011). In this case, the covalent interaction is established between the 
sulfhydryl groups of the albumin, obtained after a reduction process of the protein, and the 
sulfhydryl groups of the L-cysteine which has been attached to the polysaccharide structure 
using a carbodiimide reaction. Nanoparticles with a size range of 42-388 nm are obtained by 
this coacervation method based on a pH change that induces the disulphide bond formation 
between both structures (Fig. 9). 
 
Fig. 9. Schematic representation of preparation method of nanoparticles based on thiolated 
alginate and modified albumin, stabilized by disulphide bond formation.  
3.3 Polysaccharide-based nanoparticles with ionic cross-links 
Ionic gelation procedure to obtain nanoparticles is included among the few organic solvent 
free methods, as nanoparticles are totally synthesized in aqueous media. Compared with 
covalent cross-linking, this method shows more advantages, such as simple procedures and 
mild preparation. Nanoparticles can be obtained from aqueous solutions of charged 
polysaccharides which gel in the presence of small ions of opposite charges. Thus, 
polyanions and polycations could act as cross-linkers with polycationic and polyanionic 
polysacchraides, respectively. Very dilute solutions of the polysaccharide are used to 
perform the gelation process, in which the chains of the polymer reacting with the gelling 
agent are forming small clusters. These clusters are stabilized by forming complex with 
opposite charged electrolytes (Vauthier & Bouchemal, 2009). 
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The cationic nature of chitosan when it is dissolved in an acidic aqueous solution (pH 4-6) 
can be exploited to form nanoparticles by adding small amounts of tri-polyphosphate (TPP) 
included in an alkaline phase (pH 7-9), upon mixing of the two phases through inter and 
intra molecular linkages are created between TPP phosphates and chitosan amino groups 
(Janes et al., 2001). 
Depending on the pH and the ionic strength of the dispersing medium, these nanoparticles 
are capable of swelling and shrinking, which is used to trigger the release of a drug 
encapsulated in the nanoparticles upon the action of a pH or an ion concentration variation 
stimulus. For instance, KCl can be added to the dispersing medium to vary the ionic 
strength and cause the nanoparticle swelling; or glucosamin groups of chitosan can be 
deprotonated by raising the pH from acid to basic values causing a shrinking on the gel 
because the intramolecular electric repulsions inside the particle mesh are reduced. The 
average size of the obtained chitosan nanoparticles ranges between 20 and 400 nm (Pan et 
al., 2002). 
Some water-soluble chitosan derivatives, like N-(2-hydroxyl) propyl-3-trimethyl ammonium 
chitosan chloride or N-trimethyl chitosan, have been also ionically cross-linked to prepare 
nanoparticles. The average size of the obtained systems is between 110 and 350 nm (Amidi 
et al., 2006).  
A slightly modified ionotropic gelation technique was used by de la Fuente and coworkers 
in order to obtain nanoparticles based on chitosan and hyaluronic acid using TPP as ionic 
cross-linker. Their results show that hyaluronic acid/chitosan nanoparticles have a small 
size in the range of 110–230 nm (de la Fuente et al., 2008). 
Not only TPP is used as a cross-linker to obtain chitosan naoparticles by ionic gelation 
method. Some researchers as Kim and co-workers have obtained chitosan-based 
nanoparticles by this method using the encapsulated drug itself as a cross-linker, 
establishing electrostatic interactions between amine group of chitosan and hydroxyl group 
of the drug (Kim et al., 2006). 
Among negatively charged polysaccharides, alginate is one of the most used to obtain 
nanoparticles by ionic gelation. In this case, carboxylic groups on molecular chains of 
alginate structure can be cross-linked by bivalent calcium ions to form nanoparticles. Then, 
clusters formed in the pre-gel phase can be stabilized with polications like polylysine and 
chitosan (De & Robinson, 2003). Polylysine can form polyelectrolyte complexes with 
alginate without the previous formation of the pre-gel phase with calcium, but more 
compact nanoparticles are obtained when this previous step is carried out. The size of 
nanoparticles using polylysine as stabilizer depends, not only on the concentration of 
alginate, but also on the molecular weight. In fact, an optimal mass balance between sodium 
alginate: CaCl2: cationic polymer (poly-Llysine or chitosan) has been found to obtain 
particles with nanometric size (Vauthier & Bouchemal, 2009). Nanoparticles with an average 
size ranged between 194 nm and 1.6 µm can be obtained by this method (Ahmad et al., 2006; 
Azizi et al., 2010). 
In addition, the interaction of alginate with divalent calcium ions was used to obtain 
nanoparticles from water-in-oil microemulsions, as it was previously described (Reis et al., 
2007).  
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3.4 Methods based on self assembling macromolecules 
3.4.1 Polysaccharide based nanoparticles by polyelectrolyte complexation (PEC) 
Polyelectrolyte complexes (PECs) are formed by the interaction between oppositely charged 
polymers by intramolecular electrostatic interactions. PECs are very interesting materials for 
different applications because some of their properties, like swelling or permeability, can be 
easily modified by external stimuli, such as the pH of the medium. 
Positively or negatively charged nanoparticles with a core/shell structure can be obtained 
according to the nature of the polyelectrolyte used in excess. The hydrophobic core is 
composed by the complexed segments whereas the excess of component not incorporated in 
the polyelectrolyte complex is segregated in the outer shell ensuring the colloidal 
stabilization of the nanoparticles against coagulation and conferring the charge of the 
nanoparticle surface. This charge could affect to the interaction between cells and 
nanoparticles. Moreover, molecular weight of the two polyelectrolytes influences the size of 
the nanoparticles (Vauthier & Bouchemal, 2009).  
Although any polyelectrolyte could interact with polysaccharides in order to obtain PEC 
nanoparticles, only water-soluble and biocompatible polymers are used as polyelectrolytes 
with this goal. Among the existing polyanionic and polycationic polysaccharides to form 
PEC nanoparticles, chitosan is widely used because it satisfies the needs of safety and 
solubility. It can be seen in the literature that much research has been carried out on PECs 
with chitosan as polycation and different negative polymers, such as negative 
polysaccharides, poly(acrylic acid) (PAA) or nucleic acids. 
There is a wide variety of negative polysaccharides that can be attached to chitosan to form 
PEC nanoparticles. Carboxymethyl cellulose (Cui & Mumper, 2001), dextran-sulfate (Drogoz 
et al., 2007), alginate (Sarmento et al., 2006) and glucomannan (Alonso-Sande et al., 2006) are 
just a few examples of PEC combinations that allow the preparation of nanoparticles whose 
size ranges between 100 and 800 nm.  
The formation of the complex between chitosan and poly(acrylic acid) (PAA) has been 
widely studied. The influence of molecular weight of chitosan and PAA, the ratio of the 
initial polyelectrolyte concentrations, dropping temperature, pH of the initial solutions and 
the purification process on the size, stability and morphology of the nanoparticles has been 
studied by different authors (Chen et al., 2005; Davidenko et al., 2009).  
Nucleic acids can also be combined with chitosan to obtain nanospheres. In this case, the 
drug being the nucleic acid is incorporated in the nanocarrier as part of its structure (de 
Martimprey et al., 2009). The N/P ratio, which is defined as the ratio number of amine 
groups of the polycation (N) divided by the number of phosphate groups of the nucleic acid 
(P), has to be taken into account to obtain the desired size of nanospheres.  
Apart from chitosan, polyelectrolyte complexes with nanometric size can be formed using 
alginate, a negatively charged polysaccharide, combined with polylysine, a positively charged 
peptide (George & Abraham, 2006). Although both structures could interact without the 
previous formation of the alginate pre-gel phase with calcium, more compact nanoparticles are 
obtained when this previous step is carried out. Nanoparticles with a mean size of 250–850 nm 
are obtained using very well defined concentrations of both electrolytes. 
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3.4.2 Nanoparticles obtained from self-assembling of hydrophobically modified 
polysaccharides 
Amphiphilic copolymers are synthesized when hydrophobic segments are added to chains 
of hydrophilic polymers. In aqueous solutions, amphiphilic molecules orientate themselves 
in order to achieve a state of minimum free energy and the hydrophobic blocks are removed 
from the aqueous environment. Consequently, polymeric micelles with core/shell structure 
are formed. Thanks to their hydrophobic domain, surrounded by a hydrophilic outer shell, 
they can serve as reservoir for various hydrophobic drugs (Letchford & Burt, 2007).  
The synthesis and application of polysaccharide-based-self-aggregate nanoparticles as drug 
delivery systems have been recently investigated. There are various hydrophobic molecules 
that can be attached to polysaccharides in order to obtain these kind of systems, such as 
poly(ethylene glycol) derivatives, long chain fatty acids, poly(ɛ-caprolactone), pluronic 
copolymers, cholesterol and poly(isobutilcyanoacrylate) (PIBCA). 
Poly(ethylene glycol) (PEG) has been often used in pharmaceutical and biomedical fields as 
soluble polymeric modifier in organic synthesis, and as a pharmacological polymer with 
high hydrophilicity, biocompatibility and biodegradability. PEG and its derivatives can be 
attached to the polysaccharide structure to form micelles directly in an aqueous medium by 
adjusting the hydrophobicity/hydrophilicity of the polysaccharide chain. Chitosan has been 
grafted with different molecules of poly(ethylene glycol), obtaining nanoparticles with an 
average size ranged between 80-260 nm (Yang et al., 2008; Yoksan et al., 2004). 
Some long-chain fatty acids like hexanoic acid, linoleic acid, linolenic acid, palmitic acid or 
stearic acid have been used for modifying polysaccharides and obtaining polymeric 
micelles. Nanoparticles based on linoleic acid-chitosan have been obtained through a 
carbodiimide-mediated reaction, and their size ranged between 200-600 nm. (Chen et al., 
2003). Hu and coworkers employed a similar methodology in order to obtain stearic acid-
chitosan nanoparticles. To increase the stability of the micelle in vivo and controlled drug 
release, the shells of micelles were cross-linked by glutaraldehyde (Hu et al., 2006). Dextran 
has been also employed to obtain nanoparticles by coupling lipoic acid to the structure of 
dextran and forming nanoparticles in water, whose size varied from 145 to 221 nm (Li et al., 
2009). 
Poly(ɛ-caprolactone) (PCL) is a well known biodegradable polyester, frequently used as 
implantable carrier for drug delivery systems, and a promising molecule which allows the 
formation of nanometric micelles when it is attached with a polysaccharide structure. The 
combination of the hydroxyl groups of dextran with the carboxylic function present on 
preformed PCL monocarboxylic acid results in the formation of nanoparticles of less than 
200 nm (Lemarchand et al., 2003a). 
Hyaluronic acid and pluronics form the polymeric shell of nanoparticles obtained by Han 
and coworkers (Han et al., 2005). Pluronics self-assemble to form a spherical micellar 
structure above the lower critical solution temperature by hydrophobic interaction of the 
poly(propylene oxide) middle block in the structure. Depending on the composition and 
molecular weight, they show at high concentration a sol-gel transition behaviour when 
raising the temperature above the lower critical solution temperature, which means a 
swelling or de-swelling behaviour temperature-dependent (Liu et al., 2003).  
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Among different cyclic hydrophobic molecules, cholesterol is one of the most used to give 
hydrophobic character to polysaccharide structures and form self-assembly nanoparticles in 
aqueous solution. Cholesterol attached to pullulans of different molecular weights, or to 
chitosan, allow to obtain nanoparticles of very small sizes: 20-30 nm in case of cholesterol-
pullulans based nanoparticles (Akiyoshi et al., 1998) and 417 nm in case of cholesterol-
chitosan systems (Wang et al., 2007). Apart from cholesterol, 5ǃ-Cholanic acid is a non-toxic 
bile acid present in humans that can be chosen as the hydrophobic moiety to be attached to 
hyaluronic acid in order to form amphiphilic conjugates. The mean diameters of the 
obtained nanoparticles are in the range of 237–424 nm (Choi et al., 2010).  
Poly(isobutilcyanoacrylate) (PIBCA), which belongs to polyacrylate family, can form 
amphiphilic copolymers in combination with polysaccharide structures due to the 
hydrophobic nature of this molecule that shows carboxylic esters on its structure. Among the 
different existing combinations of PIBCA with polysaccharides, chitosan and dextran are good 
examples of hydrophilic molecules that have been used to obtain nanometric micelles though 
an emulsion polymerization of IBCA in the presence of polysaccharides. In case of chitosan, 
the obtained micelles show very small sizes, lower than 35 nm (Bertholon et al., 2006).  
3.5 Nanoprecipitation 
Nanoprecipitation is one of the most used methods to produce nanoparticles owing to the 
reproducibility, the simplicity and the economy of the technique. Systems of three 
components are needed to perform nanoprecipitation process: the polymer, the polymer 
solvent and the non-solvent of the polymer. To produce nanoparticles, the polymer solution 
is mixed with the non-solvent. Nanoparticles are instantaneously formed during the fast 
diffusion of the polymer solution in the non-solvent. This technique has been up to date 
mainly applied for poly(lactic acid), poly(lactic-co-glycolic acid) (Lassalle & Ferreira, 2007) as 
well as for polysaccharide derivatives (Hornig & Heinze, 2008). Chitosan and amphiphilic 
cycodextrins are some examples of polysaccharide derivatives employed to obtain 
nanoparticles by this method.  
In case of chitosan, sodium sulfate is commonly used as a precipitating agent to form 
chitosan particles. When sodium sulfate is slowly added into a solution of chitosan and 
polysorbate 80 under both stirring and ultrasonication, desolvated chitosan in a particulate 
form is obtained. The precipitated particles are at micro/nano interface (900 ± 200 nm) 
(Berthold et al., 1996). 
Skiba and coworkers synthesised nanoparticles based on amphiphilic cyclodextrines (Skiba 
et al., 1996). Nanospheres are prepared by progressive dispersion of an organic solution of 
modified ǃ-cyclodextrin in an aqueous phase with or without surfactant. Various 
physicochemical parameters were studied such as the effect of the chain length of acyl 
groups and type of surfactant on the size and physicochemical properties and stability of the 
nanospheres. Systems with a mean diameter varying between 90 and 150 nm were obtained 
by this method. 
4. Application as drug delivery systems 
In the design of drug carriers, issues of safety, toxicity and availability have to be taken into 
account, and the application of polysaccharides simplifies some of these issues. Thus, 
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polysaccharides are emerging as new promising materials to be applied in the design of 
drug delivery systems. Some examples of drug delivery systems that have been prepared 
during the last years using polysaccharides in their composition have been collected below 
(Table 1). 
4.1 Peptides and proteins included in polysaccharide-based delivery systems 
Some of the most significant advances in biotechnology in recent years are related with the 
discovery of some therapeutic and antigenic peptides and proteins (Vila et al., 2002). Despite 
these great advances, some problems like low stability, short biological half-life and the 
need to cross biological barriers limit the use and the in vivo application of the most of 
biologically derived drugs. The inclusion of the biologically derived drug into drug delivery 
systems based on polysaccharides have shown good results and some of the problems of 
systemic administration can be overcome. 
Insulin is one of the most widely used therapeutic peptides. It is a 5.8 kDa protein used 
exogenously to treat insulin-dependent diabetes mellitus when normal pancreatic 
production is insufficient. Orally administration of insulin normally shows low 
bioavailability due to acidic gastric pH, the enzymatic barrier of the intestinal tract and the 
physical barrier made up of the intestinal epithelium. The inclusion of insulin into nano- 
and microparticulate systems potentially provides gastric protection, controlled release and 
enhanced absorption by mucosal adhesion and nanoparticle direct uptake (Tiyaboonchai et 
al., 2003). There are various studies in which insulin has been successfully included into 
polysaccharide-based nanoparticles prepared by different methods, that have shown good 
results in loading efficacy of the drug, good release control and, in some of them, in vivo 
efficacy of the systems.  
Nanoemulsion/in situ triggered gelation is one of the methods employed to prepare insulin-
loaded nanoparticles. Pinto Reis and co-workers have designed nanoparticles based on 
alginate and alginate coated with chitosan that have been loaded with insulin obtaining an 
encapsulation efficiency between 76-93% due to the interaction of amino groups of insulin 
with carboxylic groups of alginate. They observed that insulin was strongly retained into 
both systems at low pH, but when the release medium was changed by one at near neutral 
pH, up to 40-70% of the insulin was released almost immediately. Alginate-chitosan 
nanospheres demonstrated the best controlled insulin profile release in simulated intestinal 
conditions (Reis et al., 2008). The same method has been used to prepare insulin-loaded 
nanoparticles based on alginate-dextran, achieving an encapsulation efficency of 82.5%. At 
low gastric pH, insulin was fully retained likely due to alginate polymer forming a compact 
acid-gel structure reducing permeability and potentially stabilizing insulin from acid attack. 
Up to 89% of the insulin was released almost immediately after changing the medium to 
near neutral pH, and full release was observed after 1h. Nanoencapsulated insulin was 
bioactive, which was demonstrated through both in vivo and in vitro bioassays (Reis et al., 
2007). 
Insulin-loaded nanoparticles have been prepared by ionic cross-link methods using chitosan 
as the selected polysaccharide and TPP anions as cross-linker agent. Pan and co-workers 
used this method in order to prepare chitosan nanoparticles which enhanced the intestinal 
absorption of insulin in vivo (Pan et al., 2002). The association between the drug and the 
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system was up to 80%, and the drug release was very dependent on the pH of the release 
medium. In vivo studies revealed that insulin was released in its active form, and the 
dosages of insulin loaded into chitosan nanoparticles were found orally effective, 
prolonging the hypoglycemia over 15 h.  
 
Group of 
drugs 
Entrapped 
Drug 
Method of 
synthesis 
Polysaccharide 
NP size 
(nm) 
References 
Peptides 
and 
proteins 
Insulin 
Emulsification 
/ionic gelation 
Alginate 564 Reis  
et al., 2008; 
Reis  
et al., 2007 
Alginate-chitosan 1280 
Alginate-dextran 267-2760
Ionic cross-link Chitosan 
300-400 Pan  
et al., 2002 250-400 
Polyelectrolyte 
complexation 
(PEC) 
Chitosan-dextran 
423-850 
Sarmento  
et al., 2006 Chitosan-alginate 
Chitosan-
glucomannan 
200-700 
Alonso-
Sande  
et al., 2006 
Self-assembling Pullulan-cholesterol 20-30 
Akiyoshi  
et al., 1998 
Growth 
factors 
Ionic cross-link Chitosan 301-424 
Cetin  
et al., 2007 
Antisenses Ionic cross-link Alginate-chitosan 196-430 
Azizi  
et al., 2010 
Anticancer 
drugs 
Tamoxifen 
Covalent cross-
link 
Alginate-albumin 42-388 
Martínez  
et al., 2011 
Emulsification Guar gum 200-300 
Sarmah  
et al., 2009 
Mitoxantrone Ionic cross-link Chitosan 75 
Lu  
et al., 2006 
Methotrexate Self-assembling PEG-chitosan 262 
Yang  
et al., 2008 
Doxorubicin Emulsification Oleoyl-chitosan 255 
Zhang  
et al., 2007 
Paclitaxel Self-assembling 
Stearic acid-
chitosan 
28-175 Hu et al, 2006 
Epirubicin Self-assembling 
Chitosan-
cholesterol 
417 
Wang  
et al., 2007 
Nucleic 
acids and 
genetic 
material 
Nucleic acids
Ionic cross-link Chitosan 200-700 
Katas & 
Alpar, 2006 
Polyelectrolyte 
complexation 
(PEC) 
Chitosan-alginate 323-1600
Douglas & 
Tabrizian, 
2005 
Chitosan-CMC 180-200 
Cui & 
Mumper, 
2001 
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Group of 
drugs 
Entrapped 
Drug 
Method of 
synthesis 
Polysaccharide 
NP size 
(nm) 
References 
Chitosan-nucleic 
acids 
129-450 
de 
Martimprey 
et al., 2009 
Antisenses 
Polyelectrolyte 
complexation 
(PEC) 
Alginate-poly- 
L-lysine 
28.000-
10.000 
González 
Ferreiro  
et al., 2002 
Genes 
Emulsification 
/ionic gelation 
Alginate 80 
You & Pen, 
2005 
Other 
drugs 
Furosemide
Emulsification 
/ionic gelation 
Chitosan 30-150 
Zhi  
et al., 2005 
Cyclosporine 
A 
Ionic cross-link Chitosan 250-400 
De la Fuente 
et al., 2010 
Rertinol Nanoprecipitation Chitosan 50-200 
Kim  
et al., 2006 
Antituber-
cular drugs 
Ionic gelation Alginate 236 
Ahmad et al., 
2006 
Anfortericin 
B 
Polyelectrolyte 
complexation 
(PEC) 
Chitosan-dextran 
sulfate 
600-800 
Tiyaboonchai 
& 
Limpeanchob, 
2007 
Table 1. Some groups of drugs included in polysaccharide-based nanoparticles. 
Ionotropic complexation (PEC) between chitosan and different polyanions (alginate, dextran 
sulfate and glucomannan) has been described in different works as another method that 
allowed the preparation of insulin-loaded nanoparticles. Insulin association efficiency from 
63 to 94% and loading capacity from 5 to 13% were obtained with chitosan/alginate and 
chitosan/dextran nanoparticles, providing dextran sulfate combination the highest insulin 
association efficiency. It might be seen that insulin release occurred very rapidly from both 
systems, but a significant increment of insulin retention when using dextran sulfate in the 
formulation compared with alginate was observed in simulated gastric conditions 
(Sarmento et al., 2006). Alonso-Sande and co-workers prepared insulin-loaded 
chitosan/glucomannan nanoparticles reaching association efficiency values of 89%. They 
analyzed the influence of the pH release medium and the TPP presence on the release rate, 
obtaining more restricted diffusion of the peptide through a highly cross-linked system with 
TPP and at high pH of the release medium (Alonso-Sande et al., 2006). 
Finally, nanoparticles based on self-assembling methods were also obtained and loaded 
with insulin. In this case, insulin was easily complexed with the hydrogel nanoparticle of 
hydrophobized cholesterol-bearing pullulan in water. The presence of different 
concentrations of bovine serum albumin (BSA) in the release medium was analyzed, and 
approximately 15% of insulin still remained in the complex, even at concentrations of BSA 
comparable to its physiological value in the blood. The physiological activity of complexed 
insulin was preserved in vivo after i.v. injection, showing an excellent behaviour of the 
complex as a possible protein drug carrier (Akiyoshi et al., 1998).  
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Basic fibroblast growth factor (bFGF) is a protein with molecular mass of 18 kDa that is a 
potent mitogen which regulates angiogenesis during growth and development. This growth 
factor stimulates the proliferation of a wide variety of cells, including mesenchymal, 
neuroectodermal, and endothelial cells, and it is effective on protecting neurons from 
oxidative stress processes (Li et al., 2006). However, bFGF has minimal pharmacological 
effects in the central nervous system (CNS) because of the presence of bloodbrain barrier 
that reduces its transport to CNS. In order to enhance the amount of bFGF that could reach 
the CNS, Cetin and co-workers have developed bFGF-loaded chitosan nanoparticles 
according to a ionotropic gelation process, using TPP as cross-linker agent. Nanoparticles 
displayed a low bFGF-association efficiency (27.4%) leading to final bFGF-loading values as 
low as 0.021%, but since bFGF exerts its biological activity in the concentration range of 0.1 
to 10.0 ng/mL, they concluded that the bFGF loading was acceptable. In vitro release studies 
showed that around 30% of the loaded protein was immediately released into PBS and that 
the highest extent of release (68%) was observed at 24h. Moreover, their results showed that 
integrity of the encapsulated bFGF was not affected by the entrapment procedure and 
release conditions (Cetin et al., 2007).  
Epidermal growth factor receptor (EGFR) antisense (AS) is used to reduce the expression 
of EGFR, a receptor tyrosine kinase proto-oncogene that plays a central role in the initiation 
and development of several human malignancies, notably of the breast, brain, and lung. The 
problem is that the macromolecular drug can degrade during preparation of the 
nanoparticles, during storage, and also during in vitro or in vivo release. For this reason, the 
ability of nanoparticles to protect the antisense molecules from degradation in aqueous 
medium is necessary to be investigated. Azizi and co-workers prepared EGFR-AS-loaded 
chitosan/alginate nanoparticles with different composition ratios, obtaining that 
nanoparticles can release antisense over 45-50 hours and 67-96% loading efficacy. Thus, they 
concluded that the nanoparticles could retain and stabilize the content of antisense in their 
hydrogel matrix (Azizi et al., 2010).  
4.2 Anticancer drugs included in polysaccharide-based delivery systems 
One of the major problems facing cancer chemotherapy is the achievement of the required 
concentration of the drug at the tumour site for a desired period of time, since tumours 
usually present resistances to treatment, and high dosages are frequently toxic. Thus, one of 
the main goals of nanomedicine is to develop safe and effective drug carriers that are 
systemically applied but will selectively deliver cytotoxic drugs to tumour cells without 
harming normal cells (Gullotti & Yeo, 2009). Among the available potential drug carrier 
systems in this size range, polysaccharide-based nanoparticles play an important role and 
their use with some anticancer drugs show promising results. 
Tamoxifen has been successfully used since 1970s in treatment of hormone dependent 
breast cancer (Ameller et al., 2004). However, tamoxifen shows low water solubility, which 
limits the administration of this drug only to the oral route. Furthermore, following a long-
term therapy, tamoxifen has some side effects, such as endometrial cancer and development 
of drug resistance. To overcome the undesirable side effects of tamoxifen, and to increase 
the concentration at the tumour site, tamoxifen could be entrapped into polymeric 
nanoparticles, which may provide better means of delivery in terms of enhanced uptake by 
the tumour and increased local concentration of the drug at the receptor site. Tamoxifen-
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loaded nanoparticles were prepared by Sarmah and co-workers based on guar gum, which 
is commonly used for colon specific drug delivery in the pharmaceutical industry. 
Nanoparticles were obtained by o/w emulsification and in situ polymer cross-linking, using 
dichloromethane as the best solvent of the drug and glutaraldehyde as cross-linker agent 
during the process. An efficiency loading of 15% was obtained when dichloromethane was 
used as selected solvent (Sarmah et al., 2009). Recently, nanoparticles based on thiolated 
alginate (ALG-CYS) and disulfide bond reduced albumin (BSA-SH) have been synthesized 
by coacervation method and stabilized by disulfide bond formation between both polymers. 
In vitro studies revealed that total release of the drug was not achieved in any case; only the 
23–61% of the drug was released. Maximum release took place between 7 and 75 h. 
According to the results, it was concluded that the presence of alginate in the nanoparticle 
composition allowed the modulation of the amount of released TMX (Martínez et al., 2011).  
Mitoxantrone is often used to treat breast cancer clinically, but the prolonged treatment 
with this drug results in some side-effects, such as heart toxicity and myelosupression, 
which are often a problem. Mitoxantrone is positively charged and it can be absorbed by 
negatively charged polysaccharides, such as chitosan. Nanospheres can be obtained by ion 
gelation method using sodium TPP as gelation agent, and obtaining an encapsulation 
efficacy of 98%. Tests for in vitro release in physiological saline or physiological saline 
containing 0.5% (w/v) ascorbic acid by a dialysis bag showed sustained release and little 
burst effect (Lu et al., 2006).  
Methotrexate (MTX) is a folate antimetabolite and has been used in the treatment of various 
malignancies, including childhood acute lymphocytic leukemia, osteosarcoma, non-
Hodgkin’s lymphoma, Hodgkin’s disease, head and neck cancer, lung cancer, and breast 
cancer. However, it may cause some adverse effects such as bone marrow suppression, 
acute and chronic hepatotoxicity, interstitial pneumonitis and chronic interstitial obstructive 
pulmonary disease. Therefore, in order to reduce its toxic and side effects and to improve 
specificity and selectivity, it is a good candidate to be included in drug delivery systems. 
Yang and co-workers have designed methoxy poly(ethylene glycol)-grafted-chitosan 
(mPEG-g-CS) self-aggregated nanoparticles being used as a carrier of MTX . Depending on 
the formulation, loading efficiency varied from 21 to 95%. In vitro release studies showed 
that the MTX appeared to be released in a biphasic way, which characterized by an initial 
release or rapid release period followed by a step of slower release. A fast release was 
observed in 4 h, in which 40% of the drug was released from nanoparticles. After this initial 
effect, MTX was released in a continuous way for up to 48 h, reaching percentage of 
cumulative release close to 60%. Therefore, the self-aggregated nanoparticles delayed the 
drug release in the release process when these results were compared with the release of the 
free drug (Yang et al., 2008).  
Doxorubicin (DOX) is a member of the anthracycline ring antibiotics, with a broad 
spectrum of antitumor activity, including a variety of human and animal solid tumors. 
Despite advances of this antitumor agent, it is hydrophobic and possesses inevitable, serious 
side effects such as nonspecific toxicity that limit the dose and use of the drug. Therefore, a 
lot of studies have been carried out in order to entrap this drug into different drug carriers. 
DOX has been successfully entrapped into oleoyl-chitosan nanoparticles prepared by o/w 
emulsification method. Nanoparticles had a high encapsulation efficiency of 53% in loading 
doxorubicin, being drug incorporation into nanoparticles generally limited by the large 
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surface area of the latter, as well as by the solubility of the drug in water. The drug was 
completely released from nanoparticles in the buffer medium of Na2HPO4– citric acid (pH 
3.8), whereas in PBS (pH 7.4) 65% of doxorubicin was released after 6 hours, followed by a 
sustained release until 72 hours. Approximately 72% of DOX was released for 3 days, 
showing the potential of the nanoparticles as a sustained drug delivery system, suggesting 
that the nanoparticles might act as a barrier against the release of entrapped DOX. This 
result indicated that the nanoparticles contributed to an extended circulation of DOX and 
thus an improvement in therapeutic efficacy (Zhang et al., 2007). 
Paclitaxel is an anticancer drug which is used in different types of malignancies, such as 
ovarian and breast cancer. Despite its multiple applications, it has important problems of 
solubility in water and, consequently, its administration is carried out including an oily 
component (Cremophor) and dehydrated alcohol within its formulation. Thus, relevant side 
effects such as hypersensibility, hypotension or breast pain are frequently observed after its 
intravenous administration. In the last years, a lot of studies have included this drug as 
good candidate to be included in drug delivery systems to overcome its administration 
problems. Hu and coworkers have obtained paclitaxel-loaded nanoparticles by self-cross-
linking stearic-grafted chitosan and using glutaraldehyde as cross-linker in order to stabilize 
the systems. These formulations showed high encapsulation efficiency which ranged from 
95% to 99%. When the surfaces of micelles were cross-linked by glutaraldehyde, the burst 
release of the micelles at earlier stage was highly improved and the drug release time was 
prolonged. By controlling the amino substitution of stearic-grafted chitosan and the cross-
link degree, the prolonged and controlled release could be achieved (Hu et al., 2006). 
As an anthracycline anticancer agent, epirubicin has a wide range of antitumor activity and 
is used to treat various carcinomas. However, this therapy may cause some serious side 
effects such as allergic reactions, cardiotoxicity and blood problems. Therefore, 
nanoparticles being used as a carrier of epirubicin are hoped to sustain its release, prolong 
its circulation time, enhance its therapeutic index and decrease its toxic effects. Cholesterol-
modified nanoparticles have been prepared by self-assembling method by Wang and co-
workers (Wang et al., 2007). They synthesized cholesterol-modified chitosan conjugate with 
succinyl linkages, investigated its self-aggregation behaviour, and prepared self-aggregated 
nanoparticles by sonication in aqueous media. Nanoparticles loading efficiency varied from 
25 to 71% depending on the weight ratio of epirubicin and the nanoparticles and exhibited 
the release profile relating to the pH of the release media. When the pH of the release media 
increased, an evident decrease of drug release rate was observed owing to the solubility of 
epirubicin is greatly influenced by the pH of the aqueous solution, and self-aggregated 
nanoparticles were also pH sensitive because of the presence of many amino groups in their 
molecules. Thus, the drug release from self-aggregated nanoparticles was very slow in PBS 
(pH 7.4) and the total release amount was about 25% in 48 h, which suggested self-
aggregated nanoparticles had a potential as a sustained-release carrier of epirubicin. 
4.3 Nucleic acids and genetic material included in polysaccharide-based delivery 
systems 
Small interfering RNAs (siRNAs) have proven to be versatile agents for controlling gene 
expression in mammalian cells. They have been employed as a novel tool since they can 
block the expression of genes, such as those expressed in infectious diseases and cancers. 
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However, siRNA suffers particular problems including poor cellular uptake, rapid 
degradation as well as limited blood stability. Therefore, effective systems which can protect 
and transport siRNA to the cytoplasm of the targeted cells are needed to exploit the 
promising potential applications offered by successful delivery of siRNA. Chitosan has been 
used to prepare nanoparticles based on modified ionic gelation with TPP as cross-linker 
agent, and they have been applied as possible vector that should be able to be taken up by 
the cells and escape the endosomal vesicle to avoid lysosomal degradation. In vitro study 
revealed the transfection efficiency of siRNA depends on the method of siRNA association 
to the chitosan, and entrapping siRNA using ionic gelation has shown to yield a better 
biological effect than simple complexation or siRNA adsorption onto the chitosan 
nanoparticles (Katas & Alpar, 2006).  
Ionotropic complexation (PEC) between chitosan and different polyanions has been used as 
an useful method of preparation of nanoparticles in order to include nucleic acids, since 
chitosan-DNA nanoparticles demonstrated low transfection efficiencies and the 
incorporation of secondary polymers improved the characteristics of these systems (Kaul & 
Amiji, 2002). Among the chitosan–polyanion complexes investigated, the combination of 
chitosan and alginate is considered to be among the most interesting for delivery systems. 
The method used to prepare the nanoparticles is a two-step method where the first step is 
the formation of a calcium–alginate pre-gel. Various concentrations of chitosan solutions 
were then added with continuous stirring. High loading efficacy was obtained (26-60%), 
while maximum mass loading was 60 μg DNA/mg nanoparticles and 6% and 3.5% of the 
adsorbed DNA was released. Therefore, the high encapsulation of DNA from alginate–
chitosan nanoparticles is encouraging for application in the field of gene therapy (Douglas & 
Tabrizian, 2005). The complexation between chitosan and carboxymethylcellulose (CMC) is 
another PEC combination employed in the inclusion of nucleic acid into delivery systems. 
Cui and Mumper coated the surface of this pre-formed nanoparticles with plasmid-DNA, 
obtaining a final plasmid DNA concentration of up to 400 mg/ml. Chitosan/CMC based 
nanoparticles containing plasmid DNA were applied topically to the skin of shaved mice 
and resulted in detectable and quantifiable levels of luciferase expression in skin after 24 h 
(Cui & Mumper, 2001). Nucleic acids can be also combined with chitosan in order to obtain 
nanospheres, being part of the structure of the system at the same time they are the 
encapsulant of the nanospheres. Chitosan showed a very high protection efficiency for 
siRNA. Polyplexes prepared with this polysaccharide are able to protect a siRNA for 7 h and 
an efficient transfection of the cells may be obtained after the intranasal administration of 
siRNA/chitosan polyplexes (de Martimprey et al., 2009). 
Antisense oligonucleotides are therapeutic agents known to selectively modulate gene 
expression. The development of non-parenteral dosage forms for these compounds is 
desirable. However, the high molecular weight, the hydrophilicity and multiple negative 
charges result in a poor absorption of antisense oligonucleotides. Moreover, the oral 
administration faces additional problems such as degradation in the acidic gastric 
environment, enzymatic metabolism in the lumen and at the gastrointestinal epithelium and 
first-pass hepatic clearance. To achieve a successful non-parenteral delivery of antisense 
therapeutics, it is necessary to solve the specific problems of the oral administration route, 
together with general concerns of correct time-space targeting, improved cellular uptake 
and nuclear localization to exert gene transfection (Akhtar et al., 2000). Using a ionotropic 
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gelation method, microparticles made of alginate cross-linked with calcium ions and poly-L-
lysine have been reported to effectively act as transfecting agents. Encapsulation efficacies of 
32-95% depending on the composition of the formulation have been obtained and the in 
vitro release behaviour depended mostly on the medium composition. The importance of 
competitive anions and ionic strength on the mechanism of dissociation of the 
oligonucleotide from the polymeric matrix was observed. Thus, the presence of phosphate 
anions preferably displaced alginate from the structure, resulting in the release of 
complexed oligonucleotide. Rat in vivo studies showed promising oligonucleotide 
bioavailability for microparticles after intrajejunal administration in the presence of a 
mixture of permeation enhancers to achieve a successful intestinal application (Gonzalez 
Ferreiro et al., 2002). 
Natural biopolymers are also widely used in the field of gene delivery. In fact, alginate 
nanoparticles have been prepared using w/o microemulsion as a template followed by 
calcium cross-linking of guluronic acid units of alginate polymer. Ca-alginate nanoparticles 
were loaded with GFP-encoding plasmids in order to study their potency as carriers for 
gene delivery. The degree of endocytosis by NIH 3T3 cells and ensuing transfection rate 
were investigated. Results showed that Ca-alginate nanoparticles were very efficient gene 
carriers (You & Peng, 2004). 
4.4 Other drugs included in polysaccharide-based delivery systems 
Furosemide is a loop diuretic used in the treatment of congestive heart failure and edema, 
and it has been recently incorporated into chitosan nanoparticles (Zhi et al., 2005). Since the 
chitosan molecule has strong interaction with the organic compounds, it can be applied to 
adsorb diuretics from the water samples. Zhi and coworkers prepared chitosan 
nanoparticles by a nanoemulsion system, in which the chitosan nanoparticles were prepared 
by adding NaOH solution or glutaraldehyde as the solidification solution. Size was smaller 
in case of using NaOH as cross-linker agent (30 - 150 nm). The adsorptive efficiency of 
furosemide on the nanoparticle was 51.9%, and the presence of less cross-linking agent 
could be in favour of the adsorption ability. The furosemide adsorption capacity on the 
chitosan nanoparticles was affected not only by the –NH2 content, but also by the molecular 
weight of chitosan. 
Ophthalmic drug delivery, probably more than any other route of administration, may 
benefit from the characteristics of nanotechnology-based drug delivery systems, mainly 
because of their capacity to protect the encapsulated molecule while facilitating its transport 
to the different compartments of the eye (Raju & Goldberg, 2008). For this purpose, the 
common use of chitosan is justified by its mucoadhesive and penetration enhancing 
properties, as well as by its good biocompatibility with the ocular structures. Cyclosporine 
A (CyA) is an immunosuppressant drug widely used in post-allogeneic organ transplant to 
reduce the activity of the immune system, and therefore the risk of organ rejection. The 
entrapment of the hydrophobic polypeptide CyA was achieved by ionic gelation technique 
using TPP and a previous dissolution of the peptide in an acetonitrile: water mixture, and a 
further nanoprecipitation into the nanoparticles in the form of small nanocrystals (de la 
Fuente et al., 2010). Entrapment efficiencies were reported to be as high as 73.4%. The in vivo 
evaluation of this new prototype, in rabbits, evidenced the capacity of these nanoparticles 
providing a selective and prolonged delivery of CyA to the cornea and conjunctiva. More 
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importantly, it was observed that CyA-loaded chitosan nanoparticles provided therapeutic 
levels of CyA in the conjunctiva and the cornea for up to 24 and 48 h postadministration, 
respectively, while reducing the access of CyA to the blood circulation. This positive 
behavior of chitosan nanoparticles was attributed to their improved interaction with the 
corneal and conjunctival and the prolonged delivery of the CyA molecules associated to 
them (de la Fuente et al., 2010). 
Retinol and its derivatives are extensively used in the pharmaceutical and cosmetic area. 
Especially, retinoids are recognized as being important for modern therapy of 
dermatological treatment of wrinkled skin. The stability and solubility problems of these 
compouns make them ideal candidates to be included into carriers. Nanoparticles are 
reported to be useful formulation to solve the poor aqueous solubility of retinoids and are 
able to use it by intravenous injection. Chitosan has been used by Kim and coworkers in 
order to obtain retinol-encapsulated chitosan nanoparticles for application of cosmetic and 
pharmaceutical applications (Kim et al., 2006). Retinol-encapsulated nanoparticles were 
completely reconstituted into aqueous solution as same as original aqueous solution. 
The requirement of multidrug administration daily or several times a week for at least 6 
months is the main cause of the failure of antitubercular chemotherapy. The dose-dependent 
side effects with high incidence and the need of daily-dosing results in discontinuation of 
medication, relapse of symptoms and an alarming increase in the prevalence of multidrug-
resistant strains (Pandey & Khuller, 2005). Consequently, reductions in dose and dosing 
frequency are the major goals of tuberculosis research and the application of drug delivery 
systems constitutes an important therapeutic strategy. Isoniazid, pyrazinamide and 
rifampicin, which are important antitubercular drugs, were encapsulated into alginate 
nanoparticles prepared by cation-induced gelification, reaching drug encapsulation 
efficiencies of 70–90% for isoniazid and pyrazinamide and 80–90% for rifampicin (Ahmad et 
al., 2006). When alginate nanoparticles were administered through nebulisation, the drugs 
were detected in plasma from 3 h onwards. Encapsulated drugs were observed up to 14, 10 
and 14 days, respectively, in contrast with free drugs that were cleared from the circulation 
within 12–24 h. The levels of drugs in various organs remained above the minimum 
inhibitory concentration at both doses for equal periods, demonstrating their equiefficiency. 
Alginate nanoparticles hold great potential in reducing dosing frequency of antitubercular 
drugs. 
Amphotericin B (AmB) is a polyene macrolide antifungal agent and the drug of choice for 
systemic fungal infection. Unfortunately, it is poorly absorbed from the gastrointestinal tract 
due to its low aqueous solubility and it must be given parenterally to treat systemic fungal 
infections. Currently, two types of drug formulations for AmB are available. The first one is 
a micellar solution of AmB and the second one are lipid-based nanoparticulate formulations. 
Despite these formulations reduce nephrotoxicity of the treatment, they are still quite 
expensive. Thus, much effort has been spent to develop cheaper delivery systems with 
reduced amphotericin B toxicity. Polysaccharide based nanoparticle delivery systems are 
one approach that has been investigated by Tiyaboonchai and coworkers (Tiyaboonchai & 
Limpeanchob, 2007). They prepared AmB-chitosan-dextrane sulfate nanoparticles by 
polyelectrolyte complexation at room temperature, showing an an association efficiency of 
50–65%. They observed a fast release characteristic of AmB independent of the processing 
conditions, with most of AmB released from particles within 5 min. This suggested that 
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AmB exhibited only moderate interaction with the weakly cross-linked polymers of the 
nanoparticles. A reduction of nephrotoxicity was observed in an in vivo renal toxicity study. 
5. Conclusion 
As pointed out throughout this review, polysaccharides show variability and versatility, 
due to their complex structure, which is difficult to be reproduced with synthetic polymers. 
Thus, native polysaccharides and their derivatives are emerging in the last years as one of 
the most used biomaterials in the field of nanomedicine, especially being chosen by a lot of 
researchers as carriers to be used in the preparation of nanoparticulate drug delivery 
systems. 
A wide variety of preparation methods of nanoparticles has been developed, and three 
aspects have marked the evolution of these methods: need for lees toxic agents, 
simplification of the procedures and optimization to improve yield and entrapment 
efficiency. Now it is possible to choose the best method of preparation and the best suitable 
polymer to achieve an efficient encapsulation of the drug, taking into account the drug 
features in this selection. 
As reviewed above, so many nanoparticle drug delivery systems have been prepared using 
various polysaccharides as carriers combined with different groups of drugs, and they have 
been investigated in terms of physicochemical features, drug -loading efficiency, in vitro 
toxicity and comparative in vivo test. Deeper studies, such as evaluation of interaction 
between cells, tissues and organs, as well as how the administration of these systems can 
affect to the metabolism, need to be carried out. In fact, more and more nanoparticle systems 
are emerging nowadays, and these necessary studies will be focused on in the near future, 
completing the evaluation of these hopeful polysaccharide-based systems. 
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